Login to Your Account

NYBA 21st Annual Meeting

Power to Payers: Reimbursement Is the New Approval Paradigm

By Michael Harris
Senior Editor

Monday, May 7, 2012

NEW YORK – Since payers have now replaced regulators as the Omega factor in the path to market success, the Holy Grail in drug development has transformed from regulatory approval to reimbursement – as evidenced by a trend in which some drugs have failed to live up to market expectations.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription